Option Care Home
Resources
|
Resources: Click on the link at left to go to your desired page: Introduction Page 2 Page 3 Page 4 Study 1 Study 2 Study 3 Study 4 Conclusion Post-Test Additional reading relating to each study may be found in the following citations. Study l Citation: Peter E. Lipsky MD, Desiree MFM van der Heyde MD, E. William St. Clair MD, Daniel E. Furst MD, Ferdinand C. Breedveld MD, Joachim R. Kalden MD, Josef S. Smolen MD, Michael Weisman MD, Paul Emery MD, Marc Feldmann MD, BS, PhD, Gregory R. Harriman MD, Ravider N. Maini, FRCP for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and Methotrexate in Treatment of Rheumatoid Arthritis 1.
Maini RN, Breedveld FC, Kalden JR, et.al. Infliximab and methotrexate in
the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in
Rheumatoid Arthritis with Concomitant Therapy Study Group. 2.
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor
necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid
arthritis patients receiving concomitant methotrexate: a randomized phase
III trial. ATTRACT Study Group. 3. Felson DT, Anderson JJ, Boers M, et al. The American College of
Rheumatology preliminary core set of disease activity measures for
rheumatoid arthritis clinical trials. The Committee on Outcome Measures in
Rheumatoid Arthritis Clinical Trials.
|
|
Study 2 Citation: Andreas M. Reimold, MD New Indications for Treatment of Chronic Inflammation by TNF-alpha Blockade 1. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis Rheum 2002 Jun;46(6):1451-9 2.
Aurrecoechea E, Blanco
R, Gonzalez
S, et al. Successful therapy with
infliximab in refractory adult onset Still's disease. 3.
Kraetsch HG, Antoni C, Kalden
JR, et al. Successful treatment of a small cohort of adult onset Still
disease with infliximab. 4. Targan SR,
Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's
disease. Crohn's Disease cA2 Study Group. 5. Rutgeerts P,
D'Haens G, Targan S, et al. Efficacy and safety of re-treatment with
anti-tumor necrosis factor antibody (infliximab) to maintain remission in
Crohn's disease. 6. Present DH,
Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in
patients with Crohn's disease. 7. Braun J,
Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis
with infliximab: a randomised controlled multicentre trial. 8. Van den
Bosch F, KruithofE, Baeten D, et al. Randomised double-blind comparison
of chimeric monoclonal antibody to tumor necrosis factor a (infliximab)
versus placebo in active spondyloarthropathy. 9. Chaudhari U,
Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy
for plaque-type psoriasis: a randomized trial. 10.
Honkanen
V, Lappi M, Koskinen L,
et al. Infliximab treatment in the refractory chronic uveitis of juvenile idiopathic arthritis (JIA). 11. El-Shabrawi
Y, Hermann J. Anti-TNF-a therapy with infliximab in the treatment of HLA
B27 associated acute anterior uveitis. 12. Herve P,
FIesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor
necrosis factor alpha antibody for the treatment of refractory severe
acute graft-versus-host disease. 13. Abraham E,
Wunderink R, Silvennan H, et al. Efficacy and safety of monoclonal
antibody to human tumor necrosis factor alpha in patients with sepsis
syndrome. A randomized, controlled, double-blind, multicenter clinical
trial. TNF-alpha MAb Sepsis Study Group.
|